Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - clindamycin hydrochloride - capsule - 150 milligrams per capsule - clindamycin

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - clindamycin hydrochloride - capsule - 25 milligrams per capsule - clindamycin

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - clindamycin hydrochloride - capsule - 300 milligrams per capsule - clindamycin

Ireland - English - HPRA (Health Products Regulatory Authority)

chanelle pharmaceuticals manufacturing limited - clindamycin hydrochloride - capsule - 75 milligrams per capsule - clindamycin

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 5 mg - capsule, modified release - excipient ingredients: lactose monohydrate; titanium dioxide; hypromellose; sodium lauryl sulfate; iron oxide red; magnesium stearate; iron oxide yellow; ethylcellulose; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 1 mg - capsule, modified release - excipient ingredients: hypromellose; iron oxide yellow; gelatin; sodium lauryl sulfate; titanium dioxide; ethylcellulose; iron oxide red; magnesium stearate; lactose monohydrate; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - tacrolimus, quantity: 0.5 mg - capsule, modified release - excipient ingredients: iron oxide yellow; hypromellose; iron oxide red; titanium dioxide; lactose monohydrate; ethylcellulose; magnesium stearate; sodium lauryl sulfate; gelatin; hyprolose; butan-1-ol; purified water; industrial methylated spirit; simethicone; lecithin; ethanol; shellac; strong ammonia solution; sulfuric acid - prograf-xl is indicated for use as an adjunct to liver, kidney, lung or heart allograft transplantation in adults and children.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 5 mg - capsule, hard - excipient ingredients: meglumine; pregelatinised maize starch; titanium dioxide; brilliant blue fcf; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 2.5 mg - capsule, hard - excipient ingredients: pregelatinised maize starch; meglumine; titanium dioxide; quinoline yellow; sorbitan monolaurate; allura red ac; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - ramipril, quantity: 1.25 mg - capsule, hard - excipient ingredients: meglumine; pregelatinised maize starch; titanium dioxide; iron oxide yellow; sorbitan monolaurate; potable water; gelatin; sodium lauryl sulfate - treatment of hypertension. data are currently not available to support the use of ramipril ch capsules in renovascular hypertension. post mi heart failure. prevention of progressive renal failure in patients with persistent proteinuria in excess of 1 g/day. for reducing the risk of myocardial infarction, stroke, cardiovascular death or the need for revascularisation procedures in patients 55 years of age or more who have clinical evidence of coronary artery disease, stroke, or peripheral vascular disease. for reducing the risk of myocardial infarction, stroke, cardiovascular death or revascularisation procedures in diabetic patients 55 years or more with one or more of the following risk factors: systolic blood pressure >160mmhg or diastolic blood pressure >90mmhg (or on antihypertensive treatment); total cholesterol >5.2mmol/l; hdl cholesterol <0.9mmol/l; current smoker; known microalbuminuria; any evidence of previous vascular disease.